Abstract
We have reported that serum C-reactive protein (CRP) elevation is an independent predictor of lung oxygenation impairment (LOI) after distal type acute aortic dissection (AAD). Systemic activation of the inflammatory system after aortic injury may play a role in the development of LOI. The aim of this study is to clarify the effect of beta-blockers on systemic inflammation and the development of LOI after distal type AAD. A total of 49 patients, who were admitted with distal type AAD and treated conservatively, were examined. White blood cell (WBC) count, serum CRP level, and arterial blood gases were measured serially. Forty patients received beta-blocker treatment within 24 h of the onset, while 9 patients received no beta-blocker treatment. Maximum WBC count, maximum CRP level, lowest PaO2/FiO2 (P/F) ratio, and patient background were compared between the two groups. There was no difference between the groups according to age, sex, coronary risk factors, blood pressure, serum level of CRP, WBC count, and oxygenation index on admission. Beta-blocker treatment was associated with lower maximum WBC count (P = 0.0028) and lower maximum serum CRP level (P = 0.0004). The minimum P/F ratio was higher in patients with beta-blocker treatment than in those without (P = 0.0076). Multivariate analysis revealed that administration of a beta-blocker was an independent negative determinant of LOI (P/F ratio ≤200 mmHg). In conclusion, early use of beta-blockers prevented excessive inflammation and LOI after distal type AAD, suggesting a pleiotropic effect of beta-blockers on the inflammatory response after AAD.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ, Russman PL, Evangelista A, Fattori R, Suzuki T, Oh JK, Moore AG, Malouf JF, Pape LA, Gaca C, Sechtem U, Lenferink S, Deutsch HJ, Diedrichs H, Marcos y Robles J, Llovet A, Gilon D, Das SK, Armstrong WF, Deeb GM, Eagle KA (2000) The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA 283:897–903
Suzuki T, Mehta RH, Ince H, Nagai R, Sakomura Y, Weber F, Sumiyoshi T, Bossone E, Trimarchi S, Cooper JV, Smith DE, Isselbacher EM, Eagle KA, Nienaber CA (2003) Clinical profiles and outcomes of acute type B aortic dissection in the current era: lessons from the International Registry of Aortic Dissection (IRAD). Circulation 108Suppl 1:II312–II317
Komukai K, Shibata T, Mochizuki S (2005) C-reactive protein is related to impaired oxygenation in patients with acute aortic dissection. Int Heart J 46:795–799
Sugano Y, Anzai T, Yoshikawa T, Satoh T, Iwanaga S, Hayashi T, Maekawa Y, Shimizu H, Yozu R, Ogawa S (2005) Serum Creactive protein elevation predicts poor clinical outcome in patients with distal type acute aortic dissection: association with the occurrence of oxygenation impairment. Int J Cardiol 102: 39–45
Hasegawa Y, Ishikawa S, Ohtaki A, Otani Y, Takahashi T, Sato Y, Koyano T, Yamagishi T, Ohki S, Kanda T, Morishita Y (1999) Impaired lung oxygenation in acute aortic dissection. J Cardiovasc Surg (Torino) 40:191–195
Anzai T, Yoshikawa T, Takahashi T, Maekawa Y, Okabe T, Asakura Y, Satoh T, Mitamura H, Ogawa S (2003) Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 99:47–53
Prabhu SD, Chandrasekar B, Murray DR, Freeman GL (2000) beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 101:2103–2109
Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H (2005) Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol 103:182–186
Song G, Hennessy M, Zhao YL, Li Q, Han WD, Qi Y, Zhao WN, Silke B, Barry M, Doyle R, Spiers JP (2006) Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304). Pharmacol Res 54:57–64
Wikstrand J, Berglund G, Hedblad B, Hulthe J (2003) Antiathero-sclerotic effects of beta-blockers. Am J Cardiol 91:25H–29H
Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T (2006) Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. J Cardiovasc Pharmacol 48:862–869
DeBakey ME, McCollum CH, Crawford ES, Morris GC, Jr., Howell J, Noon GP, Lawrie G (1982) Dissection and dissecting aneurysms of the aorta: twenty-year follow-up of five hundred twenty-seven patients treated surgically. Surgery 92:1118–1134
Schillinger M, Domanovits H, Bayegan K, Holzenbein T, Grabenwoger M, Thoenissen J, Roggla M, Mullner M (2002) C-reactive protein and mortality in patients with acute aortic disease. Intensive Care Med 28:740–745
Ishii T, Asuwa N (2000) Collagen and elastin degradation by matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in aortic dissection. Hum Pathol 31:640–646
Muller BT, Modlich O, Prisack HB, Bojar H, Schipke JD, Goecke T, Feindt P, Petzold T, Gams E, Muller W, Hort W, Sandmann W (2002) Gene expression profiles in the acutely dissected human aorta. Eur J Vasc Endovasc Surg 24:356–364
Sakuta A, Kimura F, Aoka Y, Aomi S, Hagiwara N, Kasanuki H (2007) Delayed enhancement on computed tomography in abdominal aortic aneurysm wall. Heart Vessels 22:79–87
Pararajasingam R, Nicholson ML, Bell PR, Sayers RD (1999) Noncardiogenic pulmonary oedema in vascular surgery. Eur J Vasc Endovasc Surg 17:93–105
Furusawa T, Tsukioka K, Fukui D, Sakaguchi M, Seto T, Terasaki T, Wada Y, Amano J (2006) The effects of a neutrophil elastase inhibitor on the postoperative respiratory failure of acute aortic dissection. Thorac Cardiovasc Surg 54:404–407
Munakata M, Itaya H, Daitoku K, Ono Y (2005) Remarkable improvement of hemodynamics by continuous hemodiafiltration in patients after operation for thoracic aortic dissection. Ann Thorac Cardiovasc Surg 11:277–280
Takahashi T, Anzai T, Yoshikawa T, Maekawa Y, Asakura Y, Satoh T, Mitamura H, Ogawa S (2003) Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction — role of neurohormones and cytokines. Int J Cardiol 88: 257–265
Murray DR, Prabhu SD, Chandrasekar B (2000) Circulation 101: 2338–2341
Bürger A, Benicke M, Deten A, Zimmer HG (2001) Am J Physiol Heart Circ Physiol 281:H14–H21
Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, Lo Cascio V, Cominacini L (2005) Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 23:589–596
Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837–846
Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T (2003) Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 107:2747–2752
Ruffolo RR Jr, Feuerstein GZ (1997) Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther 11Suppl 1: 247–256
Yue TL, Wang X, Gu JL, Ruffolo RR Jr, Feuerstein GZ (1995) Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol 294:585–591
Feuerstein GZ, Fisher M, Nunnart J, Ruffolo RR Jr (1997) Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat. Pharmacology 54:24–32
van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF (1996) Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 97:713–719
Panina-Bordignon P, Mazzeo D, Lucia PD, D’Ambrosio D, Lang R, Fabbri L, Self C, Sinigaglia F (1997) Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 100:1513–1519
Severn A, Rapson NT, Hunter CA, Liew FY (1992) Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J Immunol 148:3441–3445
Viora M, Straface E, Di Genova G, Fattorossi A, Rivabene R, Camponeschi B, Masella R, Malorni W (1997) Oxidized low density lipoproteins impair peripheral blood mononuclear cell proliferation and cytokine production. Biochem Biophys Res Commun 232:359–363
Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G (1992) Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263:92–98
Nishio R, Shioi T, Sasayama S, Matsumori A (2003) Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol 41:340–345
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jo, Y., Anzai, T., Sugano, Y. et al. Early use of beta-blockers attenuates systemic inflammatory response and lung oxygenation impairment after distal type acute aortic dissection. Heart Vessels 23, 334–340 (2008). https://doi.org/10.1007/s00380-008-1048-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00380-008-1048-7